Loading clinical trials...
Loading clinical trials...
A Post-Market, Prospective, Randomized, Controlled, Multicenter International Study to Assess the Safety of the Temporarily Implanted Nitinol Device (iTind) Compared to the UroLift® System in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH)
Conditions
Interventions
iTind
UroLift
Locations
18
United States
Mayo Clinic Arizona
Phoenix, Arizona, United States
Arizona Urology Specialists
Tucson, Arizona, United States
Urology Associates of Central California
Fresno, California, United States
Golden State Urology
Sacramento, California, United States
NorthShore University Health System Research Institute
Evanston, Illinois, United States
Southeast Louisiana Veterans Health Care System
New Orleans, Louisiana, United States
Start Date
September 26, 2022
Primary Completion Date
June 30, 2026
Completion Date
December 31, 2031
Last Updated
October 31, 2025
NCT07016620
NCT06817733
NCT06983444
NCT02026908
NCT02505919
NCT03460873
Lead Sponsor
Olympus Corporation of the Americas
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions